SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2018
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms SEESAW
- Sponsors Boehringer Ingelheim
- 18 Jan 2018 Status changed from active, no longer recruiting to completed.
- 18 Jan 2018 Planned End Date changed from 25 Apr 2018 to 28 Feb 2018.
- 02 Jan 2018 Status changed from recruiting to active, no longer recruiting.